Clinical trial · Observational
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
Short-term Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Nivolumab Plus Chemotherapy as Neoadjuvant Therapy in France
NCT06735781CI-TRIAL-00083764completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate real-world effectiveness of neoadjuvant nivolumab plus chemotherapy in France.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Neoadjuvant nivolumab plus chemotherapy treatment
- interventionNames
- Drug: Nivolumab
Primary outcomes (1)
- measure
- Rate of pathological complete response on date of surgery
- timeFrame
- Up to 31 months (until loss of follow-up, death, or end of study observation period)
Secondary outcomes (24)
- measure
- Study population baseline demographics
- timeFrame
- Baseline
- measure
- Study population baseline clinical characteristics
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Having a diagnosis of resectable non-small cell lung cancer (NSCLC) * Being 18 years or above at the time of their NSCLC diagnosis * Having initiated a neoadjuvant treatment with nivolumab and chemotherapy outside a clinical trial * Being indexed in the site database * Being followed at the site for at least 5 months, except for patients with a record of death Exclusion Criteria: • Having any primary tumor other than NSCLC on or before the date of NSCLC diagnosis that required a treatment ending less than 12-months before the nivolumab plus chemotherapy neoadjuvant treatment
References
Publications (0)
Data not yet available
No reference posted for this study.